Annexon, Inc.
ANNX · Nasdaq · United States
Share price · ANNX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ANNX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 19 Oct 2026+17.6%
Nothing announced by ANNX that day or the session before.
- 28 Sep 2026+10.2%
Nothing announced by ANNX that day or the session before.
- 15 Jul 2026+17.1%
Nothing announced by ANNX that day or the session before.
- 8 Jul 2026-7.3%
Nothing announced by ANNX that day or the session before.
- 6 Jul 2026+9.2%
Nothing announced by ANNX that day or the session before.
- 17 Jun 2026+9.3%
Nothing announced by ANNX that day or the session before.
- 10 Jun 2026-9.2%
Nothing announced by ANNX that day or the session before.
- 21 May 2026+7.9%
Nothing announced by ANNX that day or the session before.
- 15 Apr 2026+9.5%
Nothing announced by ANNX that day or the session before.
- 10 Mar 2026+8.8%
Nothing announced by ANNX that day or the session before.
Share of unusual movement by asset
For each asset, the share of ANNX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Complement C1qMonoclonal antibody | Huntington's DiseaseGuillain-Barré Syndrome | |
| Phase 3 | Complement C1qAntibody fragment | Age-Related Macular DegenerationGeographic Atrophy | |
ANX009No recent activity | Phase 1 | C1qAntibody fragment | Systemic Lupus Erythematosus |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $41M | $103M+ $111M short-term inv. | $51M-$49M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $47M | $200M+ $10.0M short-term inv. | $55M-$48M operating cash flow | report ↗ |
| 2026-Q1 | — | $36M | $176M+ $50M short-term inv. | $44M-$47M operating cash flow | report ↗ |
| 2025-Q3 | — | $50M | $140M+ $49M short-term inv. | $55M-$52M operating cash flow | report ↗ |
| 2025-Q2 | — | $44M | $133M+ $95M short-term inv. | $49M-$38M operating cash flow | report ↗ |
| 2025-Q1 | — | $48M | $98M+ $167M short-term inv. | $54M-$50M operating cash flow | report ↗ |
| 2024-Q3 | — | $30M | $81M+ $261M short-term inv. | $35M-$32M operating cash flow | report ↗ |
| 2024-Q2 | — | $25M | $158M+ $211M short-term inv. | $30M-$22M operating cash flow | report ↗ |
| 2024-Q1 | — | $21M | $153M+ $113M short-term inv. | $25M-$28M operating cash flow | report ↗ |
| 2023-Q3 | — | $28M | $134M+ $32M short-term inv. | $32M-$28M operating cash flow | report ↗ |
| 2023-Q2 | — | $30M | $115M+ $79M short-term inv. | $35M-$36M operating cash flow | report ↗ |
| 2023-Q1 | — | $32M | $145M+ $84M short-term inv. | $39M-$33M operating cash flow | report ↗ |
| 2022-Q3 | — | $28M | $212M+ $59M short-term inv. | $35M-$31M operating cash flow | report ↗ |
| 2022-Q2 | — | $29M | $106M+ $73M short-term inv. | $37M-$28M operating cash flow | report ↗ |
| 2022-Q1 | — | $27M | $114M+ $94M short-term inv. | $35M-$30M operating cash flow | report ↗ |
| 2021-Q3 | — | $28M | $70M+ $203M short-term inv. | $36M-$30M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $185M | $163M+ $76M short-term inv. | $52M-$186M operating cash flow | report ↗ |
Annexon did not report revenue for fiscal 2025. R&D expense totaled $184.7M, up 54.6% YoY, while cash, cash equivalents and short-term investments were approximately $238.3M as of December 31, 2025. The company reported a net loss of $206.69M.
The company guided to an anticipated cash runway into the second half of 2027. Clinical milestones include topline Phase 3 ARCHER II data for vonaprument in geographic atrophy expected in Q4 2026, a Marketing Authorization Application filed in Europe for tanruprubart with FORWARD study data expected to support a planned BLA submission in 2026, and proof-of-concept data for ANX1502 anticipated in 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $119M | $51M+ $263M short-term inv. | $35M-$118M operating cash flow | report ↗ |
| 2023-FY | — | $114M | $226M+ $35M short-term inv. | $34M-$121M operating cash flow | report ↗ |
| 2022-FY | — | $113M | $141M+ $103M short-term inv. | $35M-$116M operating cash flow | report ↗ |
| 2021-FY | — | $100M | $76M+ $168M short-term inv. | $33M-$106M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 9 purchases ($5.5M), 10 sales ($313K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-24 | Love Douglas · director, PRESIDENT AND CEO | Open-market purchase | 26,065 | $3.83 | $100K | Form 4 |
| 2026-08-10 | Blumenkranz Mark S. · director | Award / grant (derivative) | 175,000 | — | — | Form 4 |
| 2026-06-11 | Yednock Ted · EVP & CHIEF INNOVATION OFFICER | Option exercise | 30,646 | $1.85 | $57K | Form 4 |
| 2026-06-11 | Carson William H. · director | Award / grant (derivative) | 65,000 | — | — | Form 4 |
| 2026-06-11 | Choi Jung · director | Award / grant (derivative) | 65,000 | — | — | Form 4 |
| 2026-06-11 | Cockroft Bettina M. · director | Award / grant (derivative) | 65,000 | — | — | Form 4 |
| 2026-06-11 | JONES WILLIAM A JR · director | Award / grant (derivative) | 65,000 | — | — | Form 4 |
| 2026-06-11 | Satter Muneer A · director | Award / grant (derivative) | 65,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 217 reporting institutions held 155.9M shares ($855.6M, 82.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Redmile Group, LLC | 14,549,768 | $80.6M |
| 2 | BlackRock, Inc. | 10,938,509 | $60.6M |
| 3 | FMR LLC | 10,635,648 | $58.9M |
| 4 | BVF INC/IL | 8,698,173 | $48.2M |
| 5 | STATE STREET CORP | 6,919,255 | $38.3M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5,956,589 | $33.0M |
| 7 | Bain Capital Life Sciences Investors, LLC | 5,212,674 | $28.9M |
| 8 | Bellevue Group AG | 5,157,290 | $28.6M |
| 9 | MAK CAPITAL ONE LLC | 4,724,043 | $26.2M |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,300,000 | $23.8M |
| 11 | BANK OF AMERICA CORP /DE/ | 4,259,995 | $23.6M |
| 12 | Nuveen, LLC | 4,246,330 | $23.5M |
| 13 | Siren, L.L.C. | 3,958,646 | $21.9M |
| 14 | Balyasny Asset Management L.P. | 3,886,909 | $21.5M |
| 15 | AMERIPRISE FINANCIAL INC | 3,449,121 | $19.1M |